Moberg Pharma Q2’22: On track to Launch - Redeye

Redeye’s comments on the Q2 report that was published earlier this morning. As expected, there were no sales, and the main events during the quarter were the completed issue and the enrollment of patients for the Phase 3 study for MOB-015 in North America. With progress in the registration process, the clinical study, and other preparations for launch in 2023, Moberg Pharma is very much on track. We do not change our fair value range and Base case value of SEK 8 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/850283/moberg-pharma-q222-on-track-to-launch?utm_source=finwire&utm_medium=RSS